Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial

被引：0

作者：

Lipton, R. ^{[1
]}

Chalermpalanupap, N. ^{[2
]}

Nahas-Geiger, S. ^{[3
]}

Pozo-Rosich, P. ^{[4
]}

McAllister, P. ^{[5
]}

Tatsuoka, Y. ^{[6
]}

Liu, Y. ^{[7
]}

Dabruzzo, B. ^{[2
]}

Smith, J. ^{[7
]}

Bilchik, T. ^{[8
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY USA

[2] AbbVie, Madison, NJ USA

[3] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA USA

[4] Univ Calif Los Angeles, Los Angeles, CA USA

[5] New England Inst Neurol & Headache, Stamford, CT USA

[6] Tatsuoka Neurol Clin, Kyoto, Japan

[7] AbbVie, N Chicago, IL USA

[8] Yale Sch Med, New Haven, CT USA

来源：

HEADACHE | 2023年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-180

引用

页码：168 / 169

页数：2

共 50 条

[21] Decrease in body weight with once-daily atogepant for the preventive treatment of migraine: A post hoc analysis
Dodick, D. W.
Hay, D. L.
Walker, C. S.
Goadsby, P. J.
Ailani, J.
Severt, L.
Finnegan, M.
Ma, J.
Guo, H.
Trugman, J. M.
HEADACHE, 2022, 62 : 96 - 97
[22] Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial
Ailani, J.
Gandhi, P.
Dodick, D. W.
Reuter, U.
Schwedt, T. J.
Liu, Y.
Dabruzzo, B.
Stokes, J.
Lipton, R. B.
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[23] Patient responses to atogepant 60 mg once daily: a post hoc analysis of the ADVANCE trial
Ong, J. J. Y.
Liu, Y.
Smith, J. H.
Carr, K.
Goadsby, P. J.
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[24] Efficacy of Oral Atogepant in People With Chronic Migraine With and Without Acute Medication Overuse: Results From the PROGRESS Trial
Goadsby, Peter J.
Friedman, Deborah I.
Holle-Lee, Dagny
Demarquay, Genevieve
Ashina, Sait
Yu, Sung Y.
Dabruzzo, Brett
Guo, Hua
Schwefel, Brittany
Trugman, Joel
CEPHALALGIA, 2022, 42 (1_SUPPL) : 34 - 35
[25] Efficacy of Oral Atogepant in People With Chronic Migraine With and Without Acute Medication Overuse: Results From the PROGRESS Trial
Goadsby, P.
Friedman, D.
Holle-Lee, D.
Demarquay, G.
Ashina, S.
Yu, S.
Dabruzzo, B.
Guo, H.
Schwefel, B.
Trugman, J.
HEADACHE, 2023, 63 : 136 - 136
[26] Atogepant Provides Early Improvements in Daily Functioning and Quality of Life: Results from the PROGRESS Chronic Migraine Trial
Ailani, J.
Dodick, D.
Reuter, U.
Schwedt, T.
Liu, Y.
Dabruzzo, B.
Stokes, J.
Gandhi, P.
Lipton, R.
HEADACHE, 2023, 63 : 117 - 118
[27] Patient Responses to Atogepant 60 mg Once Daily: A Post hoc Analysis of the ADVANCE and PROGRESS Trials
Ong, Jonathan J. Y.
Liu, Yingyi
Smith, Jonathan H.
Carr, Karen
Goadsby, Peter J.
CEPHALALGIA, 2023, 43 (1supp)
[28] Monthly migraine days, acute medication use days, and migraine-specific quality of life in responders to atogepant: A post hoc analysis
Dodick, D. W.
Lipton, R. B.
Nahas, S. J.
Pozo-Rosich, P.
McAllister, P.
Mechtler, L. L.
Ma, J.
Dabruzzo, B. L.
Dufek, M.
Severt, L.
Finnegan, M.
Trugman, J. M.
HEADACHE, 2022, 62 : 152 - 153
[29] Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Dodick, D.
Lipton, R.
Nahas, S.
Pozo-Rosich, P.
McAllister, P.
Mechtler, L.
Ma, J.
Dabruzzo, B.
Dufek, M.
Severt, L.
Finnegan, M.
Trugman, J.
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[30] Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
Paul Rizzoli
Michael J. Marmura
Jennifer Robblee
Jennifer McVige
Sara Sacco
Stephanie J. Nahas
Jessica Ailani
Rosa De Abreu Ferreira
Julia Ma
Jonathan H. Smith
Brett Dabruzzo
Messoud Ashina
The Journal of Headache and Pain, 25

← 1 2 3 4 5 →